Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 5:19 PM ET

Biotechnology

Company Overview of Loxo Oncology, Inc.

Executive Profile

Joshua H. Bilenker M.D.

Founder, Chief Executive Officer, President and Director, Loxo Oncology, Inc.
AgeTotal Calculated CompensationThis person is connected to 7 Board Members in 7 different organizations across 8 different industries.

See Board Relationships
43$5,723,108
As of Fiscal Year 2014

Background

Dr. Joshua H. Bilenker, also known as Josh, MD, has been an Operating Partner at Aisling Capital LLC since November 2013. Dr. Bilenker has been the Chief Executive Officer and President of Loxo Oncology, Inc., since June 2013, which he founded in May 2013. Dr. Bilenker joined Aisling Capital LLC in April 2006. Dr. Bilenker previously served as a Principal at Aisling. He served as the Chief Financial Officer and Principal Accounting Officer of Loxo Oncology, Inc. Previously, ...

Corporate Headquarters

One Landmark Square
Stamford, Connecticut 06901

United States

Phone: 203-653-3880
Fax: --

Board Members Memberships

Director
Director
Director
2008-Present
Director, Member of Audit Committee and Member of Compensation Committee
2011-Present
Director and Chairman of Nominating & Corporate Governance Committee
2013-Present
Founder, Chief Executive Officer, President and Director

Education

MD
Johns Hopkins School of Medicine
BA
Princeton University

Other Affiliations

Annual Compensation

Salary$350,000
Total Annual Compensation$350,000

Stocks Options

Exercisable Options$333,662
Unexercisable Options$413,782
Total Number of Options$747,444

Total Compensation

Total Annual Cash Compensation$350,000
Total Short Term Compensation$350,000
Total Calculated Compensation$5,723,108
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Loxo Oncology, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.